Skip to content

Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System

Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00678899
Enrollment
50
Registered
2008-05-16
Start date
2008-04-30
Completion date
2014-07-31
Last updated
2015-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sensorineural Hearing Loss

Keywords

High frequency severe to profound

Brief summary

The purpose of this study is to evaluate the safety and efficacy associated with the provision of acoustic and electric sound processing to individuals who demonstrate significant residual low-frequency hearing and profound high-frequency (above 1500 Hz) sensorineural hearing loss. Delivery of acoustic-electric stimulation will be provided by the Nucleus Hybrid L24 cochlear implant system.

Interventions

DEVICENucleus Hybrid L24

Implantation with Nucleus Hybrid L24 cochlear implant

Sponsors

Cochlear
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Eighteen years of age or older at the time of implantation. 2. Severe to profound (a threshold average of 2000, 3000, & 4000 Hz \> 75dB HL) sensorineural hearing loss for frequencies \> 1500 Hz. Low-frequency thresholds up to and including 500 Hz should be no poorer than 60 dB HL. 3. Consonant Nucleus Consonant (CNC) monosyllabic word recognition score (mean of two lists) between 10% and 60%, inclusive (i.e., 10% \<= score \<= 60%), in the ear to be implanted. 4. CNC word recognition score in the contralateral ear equal to, or better than, the ear to be implanted but not more than 80%. 5. English spoken as a primary language.

Exclusion criteria

1. Duration of severe-to-profound hearing loss greater than 30 years. 2. Congenital hearing loss (for the purpose of this study, onset prior to 2 years-of-age). 3. Medical or psychological conditions that contraindicate undergoing surgery. 4. Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array. 5. Conductive overlay of 15 dB or greater at two or more frequencies, in the range 250 to 1000 Hz. 6. Hearing loss of neural or central origin. 7. Diagnosis of Auditory Neuropathy. 8. Active middle-ear infection. 9. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices. 10. Unwillingness or inability of the candidate to comply with all investigational requirements. 11. Additional handicaps that would prevent or restrict participation in the audiological evaluations.

Design outcomes

Primary

MeasureTime frameDescription
Consonant Nucleus Consonant (CNC) Monosyllabic Word Score-Treated Ear (CO-PRIMARY)6 Months PostactivationThe co-primary study endpoints will be statistically significant differences between the mean, preoperative monosyllabic CNC word score (unilateral acoustic, ear to be implanted) and the postoperative monosyllabic CNC word scores (Hybrid mode) for the activated, Hybrid L24 cochlear implant subjects. The CNC Words test consists of 10 recorded lists of 50 monosyllabic words in CD format. For this study, two lists will be administered in quiet at a level equal to 60 dBA in the sound field and scored as a total number of words correct, which will be expressed as a percentage correct for this study.
AzBio Sentence Score in Noise - Treated Ear (Co-Primary)6 Months PostactivationThe co-primary study endpoints will be statistically significant differences between the mean, preoperative AzBio Sentences score in noise (unilateral acoustic, ear to be implanted) and postoperative AzBio Sentences score in noise (Hybrid mode) for the activated, Hybrid L24 cochlear implant subjects. The AzBio Sentence Test consists of 15 lists of 20 sentences each. AzBio sentences are spoken by different talkers in a conversational style with limited contextual cues that the listener can use to predict or 'fill in' unintelligible words. Each list includes 5 sentences from 4 different male and female speakers. Each word in the sentence counts towards the overall score.

Secondary

MeasureTime frameDescription
Consonant Nucleus Consonant (CNC) Monosyllabic Words - Treated Ear6 Months PostactivationSecondary efficacy endpoints using binomial comparisons (based on the postoperative Hybrid condition) are as follows: The CNC Words test consists of 10 recorded lists of 50 monosyllabic words in CD format. For this study, two lists will be administered in quiet at a level equal to 60 dBA in the sound field. The percentage of subjects that scored equal to or better than they did in the pre-operative unilateral acoustic-only condition will be reported.
AzBio Sentence Score-Treated Ear6 Months PostactivationSecondary efficacy endpoints using binomial comparisons (based on the postoperative Hybrid condition) are as follows: The AzBio Sentence Test consists of 15 lists of 20 sentences each. AzBio sentences are spoken by different talkers in a conversational style with limited contextual cues that the listener can use to predict or 'fill in'unintelligible words. Each list includes 5 sentences from 4 different male and female speakers. Each word in the sentence counts toward the overall score. The percentage of subjects that scored equal to or better than they did in the pre-operative acoustic only condition will be reported.

Countries

United States

Participant flow

Participants by arm

ArmCount
Surgery
Implantation with the Nucleus Hybrid L24 Cochlear Implant
50
Total50

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse Event1

Baseline characteristics

CharacteristicSurgery
Age, Continuous64.1 years
STANDARD_DEVIATION 14.7
AzBio sentences16.3 percent correct
STANDARD_DEVIATION 14.4
Duration of hearing loss28.1 years
STANDARD_DEVIATION 14.9
Duration of severe to profound high frequency hearing loss13.1 years
STANDARD_DEVIATION 7.2
Monosyllabic words28.4 percent correct
STANDARD_DEVIATION 14.7
Sex: Female, Male
Female
25 Participants
Sex: Female, Male
Male
25 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
34 / 50
serious
Total, serious adverse events
0 / 50

Outcome results

Primary

AzBio Sentence Score in Noise - Treated Ear (Co-Primary)

The co-primary study endpoints will be statistically significant differences between the mean, preoperative AzBio Sentences score in noise (unilateral acoustic, ear to be implanted) and postoperative AzBio Sentences score in noise (Hybrid mode) for the activated, Hybrid L24 cochlear implant subjects. The AzBio Sentence Test consists of 15 lists of 20 sentences each. AzBio sentences are spoken by different talkers in a conversational style with limited contextual cues that the listener can use to predict or 'fill in' unintelligible words. Each list includes 5 sentences from 4 different male and female speakers. Each word in the sentence counts towards the overall score.

Time frame: 6 Months Postactivation

ArmMeasureValue (MEAN)Dispersion
6 Months PostactivationAzBio Sentence Score in Noise - Treated Ear (Co-Primary)49.2 percentage of words correctStandard Deviation 30.8
Primary

Consonant Nucleus Consonant (CNC) Monosyllabic Word Score-Treated Ear (CO-PRIMARY)

The co-primary study endpoints will be statistically significant differences between the mean, preoperative monosyllabic CNC word score (unilateral acoustic, ear to be implanted) and the postoperative monosyllabic CNC word scores (Hybrid mode) for the activated, Hybrid L24 cochlear implant subjects. The CNC Words test consists of 10 recorded lists of 50 monosyllabic words in CD format. For this study, two lists will be administered in quiet at a level equal to 60 dBA in the sound field and scored as a total number of words correct, which will be expressed as a percentage correct for this study.

Time frame: 6 Months Postactivation

ArmMeasureValue (MEAN)Dispersion
6 Months PostactivationConsonant Nucleus Consonant (CNC) Monosyllabic Word Score-Treated Ear (CO-PRIMARY)65.4 percentage of words correctStandard Deviation 25.4
Secondary

AzBio Sentence Score-Treated Ear

Secondary efficacy endpoints using binomial comparisons (based on the postoperative Hybrid condition) are as follows: The AzBio Sentence Test consists of 15 lists of 20 sentences each. AzBio sentences are spoken by different talkers in a conversational style with limited contextual cues that the listener can use to predict or 'fill in'unintelligible words. Each list includes 5 sentences from 4 different male and female speakers. Each word in the sentence counts toward the overall score. The percentage of subjects that scored equal to or better than they did in the pre-operative acoustic only condition will be reported.

Time frame: 6 Months Postactivation

ArmMeasureValue (NUMBER)
6 Months PostactivationAzBio Sentence Score-Treated Ear89.9 percentage of subjects
Secondary

Consonant Nucleus Consonant (CNC) Monosyllabic Words - Treated Ear

Secondary efficacy endpoints using binomial comparisons (based on the postoperative Hybrid condition) are as follows: The CNC Words test consists of 10 recorded lists of 50 monosyllabic words in CD format. For this study, two lists will be administered in quiet at a level equal to 60 dBA in the sound field. The percentage of subjects that scored equal to or better than they did in the pre-operative unilateral acoustic-only condition will be reported.

Time frame: 6 Months Postactivation

ArmMeasureValue (NUMBER)
6 Months PostactivationConsonant Nucleus Consonant (CNC) Monosyllabic Words - Treated Ear96 percentage of subjects

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026